Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027

Stroke is caused by the interruption of the blood supply to the brain, usually because a cerebral blood vessel ruptures and bleeds (hemorrhagic stroke) or is blocked by a clot (ischemic stroke), which obstructs blood flow and oxygen and nutrients from reaching the brain, causing death of the local brain tissue (infarction). Stroke is a leading cause of disability and death worldwide and a common cause of dementia, associated with significant social and economic impact. The acute ischemic stroke (AIS) market is about to enter an exciting phase over the next decade with novel therapies entering the market that are designed to improve stroke outcome. The arrival of three novel neuroprotective agents (NA-1, BIIB093, and 3K3A-APC) and one stem cell therapy (MultiStem) are aimed at improving clinical outcome post-stroke when given in the acute phase of stroke, along with Activase or endovascular treatment (EVT) or both. One stem cell therapy, SB623, is designed to reduce disability in patients with chronic stroke, potentially given years after the initial event.

GlobalData estimates that sales of drugs in the AIS market (including TIA) were approximately $7.2B in 2017 in the 8MM. The US was the largest market, with sales of $3.4B, representing 47% of all sales from the 8MM. The highest-selling drug in the market was Roche’s Activase (alteplase), which generated sales of $1.2B in the 8MM in 2017.

Key Questions Answered

What are the key drivers of significant growth of the AIS market?

What are the pricing and reimbursement prospects for the upcoming novel therapies?

What is the market potentials of drugs developed for the treatment of AIS, and would they fulfil the greatest unmet needs in this space?

How will key patent expiries of novel anticoagulants (NOACs) impact sales of current and launching therapies in AIS?

Will there be opportunities remaining after the launch of late pipeline drugs in AIS?

Scope

Overview of AIS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized AIS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AIS therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global AIS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global AIS therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AIS therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

Roche

Boehringer Ingelheim

Bristol-Myers Squibb

Janssen

Daiichi Sankyo

AstraZeneca

ZZ Biotech

NoNO Inc.

Biogen

Athersys

SanBio

Roche

Boehringer Ingelheim

Bristol-Myers Squibb

Janssen

Daiichi Sankyo

AstraZeneca

ZZ Biotech

NoNO Inc.

Biogen

Athersys

SanBio

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Acute Ischemic Stroke: Executive Summary

2.1 AIS Market Forecast to Reach $10.6B ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Acute Ischemic Stroke: Executive Summary

2.1 AIS Market Forecast to Reach $10.6B by 2027

2.2 The AIS Late-Stage Pipeline Focus on Improving Stroke Outcome

2.3 Current Treatments Leave High Level of Unmet Need in the AIS Market

2.4 Opportunities Will Remain for New Entrants

2.5 Late-Stage Pipeline Drugs Entering the AIS Market Will Be a Key Driver of Growth

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for AIS (2017–2027)

5.5.1 First-Ever Diagnosed Incident Cases of AIS

5.5.1 Age-Specific First-Ever Diagnosed Incident Cases of AIS

5.5.2 Sex-Specific First-Ever Diagnosed Incident Cases of AIS

5.5.3 Recurrent Diagnosed Incident Cases of AIS

5.5.4 First-Ever Diagnosed Incident Cases of AIS by TOAST Subtype

5.5.5 Diagnosed Prevalent Cases of AIS

5.5.6 Age-Specific Diagnosed Prevalent Cases of AIS

5.5.7 Sex-Specific Diagnosed Prevalent Cases of AIS

5.5.8 AIS Mortality

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 AIS

6.1.2 TIA

6.2 Treatment Guidelines

6.3 US

6.4 5EU

6.5 Japan

6.6 China

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Safer and More Effective Thrombolysis

8.3 Effective Therapies to Improve Clinical Outcome

8.4 Long-Term Compliance with Secondary Stroke Prevention Therapies

8.5 Access to Rapid Diagnosis and Acute Treatment

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 Neuroprotective Agents

9.2.2 Stem Cell Therapies

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Roche Portfolio Assessment

10.4 Boehringer Ingelheim Portfolio Assessment

10.5 Bristol-Myers Squibb Portfolio Assessment

10.6 Janssen Portfolio Assessment

10.7 Daiichi Sankyo Portfolio Assessment

10.8 AstraZeneca Portfolio Assessment

10.9 ZZ Biotech Portfolio Assessment

10.10 NoNO Inc. Portfolio Assessment

10.11 Biogen Portfolio Assessment

10.12 Athersys Portfolio Assessment

10.13 SanBio Portfolio Assessment

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 China

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.4.2 Primary Research – Prescriber Survey

12.5 About the Authors

12.5.1 Analyst

12.5.2 Therapy Area Director

12.5.3 Epidemiologist

12.5.4 Managing Epidemiologist

12.5.5 Global Director of Therapy Analysis and Epidemiology

12.5.6 Global Head and EVP of Healthcare Operations and Strategy

12.6 About GlobalData

12.7 Contact Us

12.8 Disclaimer

List of Tables

Table 1: AIS: Key Metrics in the 8MM

Table 2: TOAST Classification of Subtypes of AIS

Table 3: Risk Factors and Comorbidities for AIS

Table ...

Table 1: AIS: Key Metrics in the 8MM

Table 2: TOAST Classification of Subtypes of AIS

Table 3: Risk Factors and Comorbidities for AIS

Table 4: Evaluation of Patients with Suspected Acute Ischemic Stroke or Transient Ischemic Attack

Table 5: Criteria for Thrombolysis Using Activase in Patients with AIS

Table 6: ABCD2 Score Used for Risk of Stroke Assessment

Table 7: Treatment Guidelines for AIS and TIA

Table 8: Country Profile – US

Table 9: Country Profile – 5EU

Table 10: Country Profile – Japan

Table 11: Country Profile – China

Table 12: Leading Treatments for AIS and TIA, 2018

Table 13: Roche’s AIS/TIA Portfolio Assessment, 2018

Table 14: Boehringer Ingelheim’s AIS Portfolio Assessment, 2018

Table 15: Bristol-Myers Squibb’s AIS Portfolio Assessment, 2018

Table 16: Janssen’s AIS Portfolio Assessment, 2018

Table 17: Daiichi Sankyo’s AIS Portfolio Assessment, 2018

Table 18: AstraZeneca’s AIS Portfolio Assessment, 2018

Table 19: ZZ Biotech’s AIS Portfolio Assessment, 2018

Table 20: NoNO Inc.’s AIS Portfolio Assessment, 2018

Table 21: Biogen’s AIS Portfolio Assessment, 2018

Table 22: Athersys’ AIS Portfolio Assessment, 2018

Table 23: SanBio’s AIS Portfolio Assessment, 2018

Table 24: AIS Market – Global Drivers and Barriers, 2017–2027

Table 25: Key Events Impacting Sales for AIS and TIA in the US, 2017–2027

Table 26: AIS Market – Drivers and Barriers in the US, 2017–2027

Table 27: Key Events Impacting Sales for AIS in the 5EU, 2017–2027

Table 28: AIS Market – Drivers and Barriers in the 5EU, 2017–2027

Table 29: Key Events Impacting Sales for AIS in Japan, 2017–2027

Table 30: AIS Market – Global Drivers and Barriers in Japan, 2017–2027

Table 31: Key Events Impacting Sales for AIS in China, 2017–2027

Table 32: AIS Market – Global Drivers and Barriers in China, 2017–2027

Table 33: Key Historical and Projected Launch Dates for AIS

Table 34: Key Historical and Projected Patent Expiry Dates for AIS

Table 35: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

Figure 1: Global Sales Forecast by Country for AIS in 2017 and 2027

Figure 2: Analysis of the Company Portfolio Gap in AIS During the ...

Figure 1: Global Sales Forecast by Country for AIS in 2017 and 2027

Figure 2: Analysis of the Company Portfolio Gap in AIS During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of AIS During the Forecast Period

Figure 4: Main Types and Processes of Acute Ischemic Stroke (AIS) and Its Management

Figure 5: Stroke-Induced Neuronal Cell Death and Therapeutic Targets of Pipeline Candidates

Figure 6: 8MM, Age-Standardized First-Ever Diagnosed Incidence of AIS, Men, Ages ≥18 Years, 2007–2027

Figure 7: 8MM, Age-Standardized First-Ever Diagnosed Incidence of AIS, Women, Ages ≥18 Years, 2007–2027

Figure 8: 8MM, Age-Standardized Diagnosed Prevalence of AIS, Men, Ages ≥18 Years, 2007–2027

Figure 9: 8MM, Age-Standardized Diagnosed Prevalence of AIS, Women, Ages ≥18 Years, 2007–2027

Figure 10: Sources Used and Not Used for First-Ever Diagnosed Incident Cases of AIS

Figure 11: Sources Used and Not Used for Recurrent Diagnosed Incident Cases of AIS

Figure 12: Sources Used and Not Used for First-Ever Diagnosed Incident Cases of AIS by TOAST Subtype

Figure 13: Sources Used and Not Used for Diagnosed Prevalent Cases of AIS

Figure 14: Sources Used and Not Used for AIS Mortality

Figure 15: 8MM, First-Ever Diagnosed Incident Cases of AIS, Men and Women, Ages ≥18 Years, 2017

Figure 16: 8MM, Age-Specific First-Ever Diagnosed Incident Cases of AIS, Men and Women, 2017

Figure 17: 8MM, Sex-Specific First-Ever Diagnosed Incident Cases of AIS, Ages ≥18 Years, 2017

Figure 18: 8MM, Recurrent Diagnosed Incident Cases of AIS, Ages ≥18 Years, Men and Women, 2017

Figure 19: 8MM, First-Ever Diagnosed Incident Cases of AIS by TOAST Subtype, Ages ≥18 Years, Men and Women, 2017

Figure 20: 8MM, Diagnosed Prevalent Cases of AIS, Men and Women, Ages ≥18 Years, 2017

Figure 21: 8MM, Age-Specific Diagnosed Prevalent Cases of AIS, Men and Women, 2017

Figure 22: 8MM, Sex-Specific Diagnosed Prevalent Cases of AIS, Ages ≥18 Years, 2017

Figure 23: 8MM, AIS Mortality, Ages ≥18 Years, Men and Women, 2017-2027

Figure 24: Acute Ischemic Stroke Management

Figure 25: Transient Ischemic Attack Management

Figure 26: Unmet Needs and Opportunities in AIS and TIA

Figure 27: Overview of the Development Pipeline in AIS and TIA

Figure 28: Key Phase II/III Trials for the Promising Pipeline Agents That GlobalData Expects to Be Licensed for AIS or TIA or Both in the 8MM During the Forecast Period

Figure 29: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of AIS During the Forecast Period

Figure 30: Analysis of the Company Portfolio Gap in AIS and TIA During the Forecast Period

Figure 31: Global (8MM) Sales Forecast by Country for AIS and TIA Combined in 2017 and 2027

Figure 32: Sales Forecast by Class for AIS and TIA Combined in the US in 2017 and 2027

Figure 33: Sales Forecast by Class for AIS and TIA Combined in the 5EU in 2017 and 2027

Figure 34: Sales Forecast by Class for AIS and TIA Combined in Japan in 2017 and 2027

Figure 35: Sales Forecast by Class for AIS and TIA Combined in China in 2017 and 2027

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports